Futura Medical Regulatory News (FUM)

8 June 2023

  Futura Medical plc

("Futura" or the "Company")

Futura Medical Announces Investor Seminar

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce that it will be hosting an Investor Seminar on the 22 June 2023 in London for analysts and institutional investors. Following the Investor Seminar, an Investor Meet Company meeting will be held for Retail Investors on Monday the 26 June.

The Investor Seminar follows a milestone year to date following the UK launch on the 18 April 2023 of MED3000 under the brand name Eroxon® with Cooper Consumer Health, its EU and UK distribution partner, and online launches in Europe and in retail pharmacies in Belgium.

The Investor Sseminar will feature presentations from Futura as well as eminent Key Opinion Leaders (KOLs) Dr Jeff Foster, BSc, (Hons), MB ChB, DRCOG, MRCGP, men's health specialist and book author and Dr Janine David, FECSM, GP who specialises in Men and Women's sexual health and will close with a presentation by Mark Berkhout, International Marketing Director for Cooper Consumer Health & Jon Connolly Marketing Director Ceuta Healthcare

For further information on the Investor Seminar, or to register your interest, please contact Optimum Strategic Communications at futuramedical@optimumcomms.com. Further information will be made available closer to the event.

A recording will be made available through a webcast which can be accessed via the investor section of the Futura website shortly after the event. No new material disclosures will be made at the event.

The Retail Investor event is scheduled for Monday 26 June at 10:00am with Investor Meet Company. Retail Investors can sign up to Investor Meet Company for free via www.investormeetcompany.com.

-ENDS-

For further information, please contact:

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has previously conducted an initial Phase 3 study using MED3000 in ED, referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A second confirmatory Phase 3 clinical study, "FM71" was also conducted to support Futura's regulatory submission to the FDA with 96 ED patients and endpoints at 24 weeks, demonstrating that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.

Eroxon® is CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon®, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference

to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.